Skip to main content

Table 2 Clinical and laboratory characteristics of the studied cytogenetic groups

From: Clinical impact of early minimal residual disease detection at day 15 in precursor B-childhood acute lymphoblastic leukemia: an Egyptian experience

Parametert (9;22) n = (4)t(1;19) n = (8)11q23 rearrangement n = (4)
Age
 <1 year-042
 1–9 years242
> 10 years200
Sex
 Male462
 Female022
Clinical data 
 Hepatomegaly482
 Splenomegaly444
 Lymphadenopathy480
 CNS infiltration202
Laboratory data (at diagnosis)Mean (± SD)Mean (± SD)Mean (± SD)
 TLC (× 109/L)86.1 ± 48.987.4 ± 44.8189.25 ± 17.04
 Hb (gm/dl)6.7 ± 1.17.93 ± 2.129.05 ± 1.63
 Platelets(× 109/L)46.5 ± 7.749.75 ± 34.0755.50 ± 13.44
 Peripheral blood blasts (%)29.0 ± 4.228.0 ± 28.9318.50 ± 3.54
 Blasts in B.M (%)68.5 ± 3.558.5 ± 18.2763.5 ± 38.89
Laboratory data (at day 15 of induction)Mean (± SD)Mean (± SD)Mean (± SD)
 TLC (× 109/L)1.8 ± 1.41.25 ± 0.451.80 ± 1.41
 Hb (gm/dl)7.7 ± 0.47.8 ± 1.147.85 ± 0.49
 Platelets(× 109/L)110.5 ± 27.651.0 ± 29.4669.5 ± 23.33
 Blasts in B.M (%)12.5 ± 13.410.25 ± 7.513.50 ± 7.78
MRD status at day 15 
 Good outcome220
 Bad outcome264
  1. TLC total leukocytic count, Hb hemoglobin, PB peripheral blood, BM bone marrow, SD standard deviation, n number